Comparative Efficacy of Two Once Daily Methylphenidate Formulations (Ritalin?? LA???1 and Concerta??) and Placebo in Children with Attention Deficit Hyperactivity Disorder Across the School Day

López, Frank A.; Silva, Raul; Pestreich, Linda; Muniz, Rafael

doi:10.2165/00148581-200305080-00005

Cited by 66 publications

(48 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, children's behavior while on MLR MPH or IR MPH displayed an initial improvement, subsequently remaining constant over time. These results indicate that ADHD symptoms are somewhat mild in the morning and increase in severity throughout the day and confirm previous findings (Pelham et al 2001;Lopez et al 2003). Both MLR MPH and IR MPH prevented this behavioral deterioration but placebo did not.…”

Section: Figsupporting

confidence: 91%

“…The CPT is a widely used cognitive task that measures patient attention and has been shown to be sensitive to MPH treatment effects in children with ADHD (Pelham et al 1987;Pelham et al 1990;Riccio et al 2001). Previous studies have shown improvements in commission and/or omission errors in children with ADHD treated with MPH (Aman et al 1987;Aman et al 1991;Losier et al 1996). In this study following MPH treatment, the number of omission errors dropped significantly compared to placebo, whereas the number of commission errors, or false positives, remained constant.…”

Section: Figmentioning

confidence: 99%

See 1 more Smart Citation

Cognitive and Behavioral Effects of Multilayer-Release Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder

Schachar

Ickowicz

Crosbie

et al. 2008

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: The aim of this study was to compare the pharmacodynamics of a new multilayerrelease (MLR) formulation methylphenidate (MPH; Biphentin ® ) with immediate-release (IR) MPH (Ritalin ® ) in a double-blind, cross-over, placebo-controlled study in patients with attention-deficit/hyperactivity disorder (ADHD). Conclusions: MLR MPH given once daily produces equivalent improvements in behavioral and cognitive measures, and has a duration of effect at least as long as that of IR MPH given twice daily. 11

show abstract

Section: Figsupporting

confidence: 91%

Section: Figmentioning

confidence: 99%

Cognitive and Behavioral Effects of Multilayer-Release Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder

Schachar

Ickowicz

Crosbie

et al. 2008

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…23 Ritalin LA ® capsules have also been compared to Concerta ® in a single-blind, placebo-controlled, crossover study. 24 In the study, Ritalin LA 28 Transdermal delivery of methylphenidate provides a treatment option for children who have difficulty swallowing oral medications or if they would benefit from tailoring the duration of effect specifically for their daily needs. 29 The Daytrana ® patch is a multipolymeric adhesive platform that is designed to release methylphenidate consistently upon application to intact skin.…”

mentioning

confidence: 99%

Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder

Sugrue

Bogner

Ehret

2014

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Abstract:Purpose: To review the current literature on the various extended-release methylphenidate stimulant preparations regarding safety and efficacy in children and adolescents with attentiondeficit/hyperactivity disorder (ADHD). Conclusions: Extended-release methylphenidate is effective in treating the symptoms of ADHD in children and adolescents. The different available dosage forms gives the clinician the opportunity to individualize treatment based on patient needs. * Data Sources: The literature included was retrieved from PubMed/MEDLINE using the terms methylphenidate, stimulant, extended-release, children, and attention/hyperactivity disorder. Reference citations from publications identified were also reviewed. SummaryStudy Selection and Data Extraction: Double-blind clinical trials found using the search strategy above were included in this review. Open-label studies were included if no double-blind trials were published for that methylphenidate preparation.

show abstract

“…Medication for ADHD has traditionally been with indirect dopamine agonists, of which methylphenidate is the most commonly used drug [18,19]. The participants with ADHD tested in the present study were all medicated with methylphenidate.…”

Section: Introductionmentioning

confidence: 99%

Associative learning in ADHD: improved expression under methylphenidate

Kantini¹,

Cassaday²,

Batty³

et al. 2011

OJPsych

View full text Add to dashboard Cite

Attention Deficit/Hyperactivity Disorder (ADHD) is characterised by developmentally inappropriate levels of inattention, impulsivity and hyperactivity. As might be expected of a disorder in which inhibitory deficits form part of the diagnostic criteria, deficits in response inhibition in ADHD have been evidenced in a number of studies. To date, the tasks used in such studies have required participants to inhibit the learned stimulus-response associations that result in unwanted behavior. However, no research has examined the inhibition of stimulus-stimulus associations, formally 'conditioned inhibition'. The present study used video game style conditioned inhibition procedures, developed for children and adolescents with a clinical diagnosis of ADHD and suitable for typically developing matched controls. Two computer-based tasks ('Mission to Mars' and 'Weapon-X') required participants to predict the occurrence of an outcome based on the stimuli presented. We selected 12 male participants with ADHD on medication (methylphenidate), but without comorbid Tourette Syndrome, pervasive developmental disorder, learning disability or psychosis. This group showed overall normal inhibition of stimulus-stimulus associations, measured repeatedly over trials and with two task variants. There was no correlation between inhibitory learning and symptom severity ratings. However, participants with ADHD on higher dosages of methylphenidate, or longer duration of treatment with methylphenidate, showed improved ability to anticipate outcomes following the different stimulus presentations on non-inhibited versus inhibited trials. This effect was most clearly demonstrated on the Weapon-X task. Thus, methylphenidate dose-relatedly improved the expression of associative learning. This action may contribute to its therapeutic effects in improving cognitive function in ADHD.

show abstract

Comparative Efficacy of Two Once Daily Methylphenidate Formulations (Ritalin?? LA???1 and Concerta??) and Placebo in Children with Attention Deficit Hyperactivity Disorder Across the School Day

Abstract: While both Ritalin LA and Concerta were shown to be effective, the different release profiles of each formulation can result in distinct differences between the effects on measures of attention and deportment.

Cited by 66 publications

References 7 publications

Cognitive and Behavioral Effects of Multilayer-Release Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder

Cognitive and Behavioral Effects of Multilayer-Release Methylphenidate in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder

Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder

Associative learning in ADHD: improved expression under methylphenidate

Contact Info

Product

Resources

About